Pre-surgical level of von Willebrand factor as an evident indicator of breast cancer recurrence

Rhone, Piotr; Zarychta, Elżbieta; Bielawski, Kornel; Ruszkowska-Ciastek, Barbara

doi:10.3233/cbm-191096

Cited by 9 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High levels of VWF were also associated with a worse survival even in lower grade gliomas [ 145 ]. There is a positive correlation between VWF concentration and invasive breast carcinoma, with higher VWF to serum soluble E-selectin ratios being associated with poorly differentiated tumors [ 146 ]. However, contrary to this association, extremely high levels of VWF and a lower VWF/soluble E-selectin ratio was associated with better survival rates and lower relapse risk in the same patients [ 146 ].…”

Section: Vwf and Adamts13 As Cancer Biomarkersmentioning

confidence: 99%

“…There is a positive correlation between VWF concentration and invasive breast carcinoma, with higher VWF to serum soluble E-selectin ratios being associated with poorly differentiated tumors [ 146 ]. However, contrary to this association, extremely high levels of VWF and a lower VWF/soluble E-selectin ratio was associated with better survival rates and lower relapse risk in the same patients [ 146 ]. An elevated VWF/ADAMTS13 ratio was shown to be independently associated with poor prognosis and mortality in patients with advanced non-small-cell lung cancer (NSCLC) [ 128 ].…”

Section: Vwf and Adamts13 As Cancer Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer

2022

View full text Add to dashboard Cite

von Willebrand factor (VWF) is a complex and large protein that is cleaved by ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13), and together they serve important roles in normal hemostasis. Malignancy can result in both a deficiency or excess of VWF, leading to aberrant hemostasis with either increased bleeding or thrombotic complications, as respectively seen with acquired von Willebrand syndrome and cancer-associated venous thromboembolism. There is emerging evidence to suggest VWF also plays a role in inflammation, angiogenesis and tumor biology, and it is likely that VWF promotes tumor metastasis. High VWF levels have been documented in a number of malignancies and in some cases correlate with more advanced disease and poor prognosis. Tumor cells can induce endothelial cells to release VWF and certain tumor cells have the capacity for de novo expression of VWF, leading to a proinflammatory microenvironment that is likely conducive to tumor progression, metastasis and micro-thrombosis. VWF can facilitate tumor cell adhesion to endothelial cells and aids with the recruitment of platelets into the tumor microenvironment, where tumor/platelet aggregates are able to form and facilitate hematogenous spread of cancer. As ADAMTS13 moderates VWF level and activity, it too is potentially involved in the pathophysiology of these events. VWF and ADAMTS13 have been explored as tumor biomarkers for the detection and prognostication of certain malignancies; however, the results are underdeveloped and so currently not utilized for clinical use. Further studies addressing the basic science mechanisms and real word epidemiology are required to better appreciate the intriguing connections between VWF, ADAMTS13 and malignancy. A better understanding of the role VWF and ADAMTS13 play in the promotion and inhibition of cancer and its metastasis will help direct further translational studies to aid with the development of novel cancer prognostic tools and treatment modalities.

show abstract

Section: Vwf and Adamts13 As Cancer Biomarkersmentioning

confidence: 99%

Section: Vwf and Adamts13 As Cancer Biomarkersmentioning

confidence: 99%

The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer

2022

View full text Add to dashboard Cite

show abstract

“…Disease progression and worse future prognosis were associated with high vWF levels by Dhami et al, who suggest that the vWF concentration may serve as an independent prognostic marker in neoplastic disease [ 20 ]. Rhone et al noted opposite results since a lower concentration of vWF was related to a shorter survival rate [ 21 ]. Discrepancies in this regard might be associated with an unrevealed role of vWF in cancerogenesis.…”

Section: Introductionmentioning

confidence: 99%

Complex Analysis of Endothelial Markers as Potential Prognostic Indicators in Luminal Invasive Breast Carcinoma Patients: Outcomes of a Six-Year Observational Study

Kwiatkowska,

Rhone,

Koziorzemska

et al. 2023

Biomedicines

Self Cite

View full text Add to dashboard Cite

(1) Background: Metastasis is a complex process in which the primary cancer cells spread to a distant organ or organs, creating a secondary tumor location, which in many patients leads to treatment failure and death. The aim of the present study was to assess the association of endothelial markers (i.e., sP-selectin, sE-selectin and von Willebrand factor) with the leptin-to-adiponectin ratio (LAR) and to perform an analysis of the predictive value on the survival of patients with luminal A and B invasive breast cancer (IBrC). (2) Methods: The trial included 70 treatment-naïve early-stage IBrC patients with a median age of 54.5 years and a median tumor diameter of 1.5 cm. The median duration of follow-up was 5.7 years, with a relapse rate of 15.71%. Specific immunoenzymatic kits were used to determine pre- and post-treatment concentrations of analyzed factors. (3) Results: Regardless of the treatment pattern, endothelial marker concentrations and the LAR increased after adjuvant treatment. The follow-up showed a significantly higher relapse rate in patients with IBrC who had higher pre-treatment sP-selectin and post-treatment LAR levels. According to receiver operating characteristic (ROC) analysis, a post-treatment LAR with a sensitivity of 88.9% and specificity of 57.9% discriminating cases with or without disease relapse. Additionally, a higher risk of breast cancer relapse was associated with a lower post-treatment sP-selectin concentration. (4) Conclusions: Our results showed mainly that pre-treatment sP-selectin levels and post-treatment LAR may have value as prognostic indicators and may contribute to predicting the future outcomes in patients with early-stage IBrC.

show abstract